Santhera Pharmaceuticals【0QN1】銘柄情報

Santhera Pharmaceuticals Holding AG (0QN1) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

19.02

( - )

買値

19.02

売値

19.02

出来高

269

0.00 日の範囲 0.00

19.02 52 週間の範囲 19.02

時価総額

282.157M

前日終値

19.02

始値

時刻

15.70047

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

CHF 89,596

発行済株式数

14,834,734

配当利回り

PER

-4.18

1 株当たり利益 (EPS)

-3.78

歳入

77.19M

純利益

-49.24M

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamo... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland. 詳細を表示

セクター

業界

ウェブサイト

www.santhera.com

本社

Pratteln, Switzerland

設立

2026

Santhera Pharmaceuticals Holding AG is listed in the sector of the ロンドン証券取引所 with ticker 0QN1. The last closing price for Santhera Pharmaceuticals was CHF19.02. Over the last year, Santhera Pharmaceuticals shares have traded in a share price range of CHF 19.02 to CHF 19.02.

Santhera Pharmaceuticals currently has 14,834,734 shares in issue. The market capitalisation of Santhera Pharmaceuticals is CHF282.16 million. Santhera Pharmaceuticals has a price to earnings ratio (PE ratio) of -4.18.

European Stocks Edge Higher After Wall Street’s Record Finish: DAX, CAC, FTSE100

European equities traded mostly in positive territory on Monday, taking cues from Wall Street, where major indices closed the previous week at...

Santhera publiziert Zeitplan für die Aktienzusammenlegung

Santhera publiziert Zeitplan für die Aktienzusammenlegung NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER...

Santhera’s Aktionäre stimmen an heutiger Generalversammlung allen Anträgen des Verwaltungsrats zu

Santhera’s Aktionäre stimmen an heutiger Generalversammlung allen Anträgen des Verwaltungsrats zu Pratteln, Schweiz, 27. Juni 2023 –...

Santhera vergibt exklusive Nordamerika-Lizenz für Vamorolone an Catalyst Pharmaceuticals in einer Transaktion im Wert von bis zu USD 231 Millionen zuzüglich Lizenzgebühren

Santhera vergibt exklusive Nordamerika-Lizenz für Vamorolone an Catalyst Pharmaceuticals in einer Transaktion im Wert von bis zu USD 231...

Santhera Publishes Agenda for its Annual General Meeting

Santhera Publishes Agenda for its Annual General Meeting NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER...

Santhera veröffentlicht Jahresbericht 2022

Santhera veröffentlicht Jahresbericht 2022 Ad-hoc-Mitteilung gemäss Art. 53 KR Pratteln, Schweiz, 31. Mai 2023 – Santhera Pharmaceuticals...

期間 †	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	DE
4	0	0	0	0	0	DE
12	0	0	0	0	0	DE
26	19.02	19.02	19.02	8037	19.02	DE
52	19.02	19.02	19.02	4828	19.02	DE
156	19.02	190.2	19.02	2204	75.66135255	DE
260	19.02	190.2	19.02	2423	48.85244433	DE